NaviGate Cardiac Structures, Inc. Reports “Exceptional” Six-Week Results for Two Implantations of Its GATE™ Atrioventricular Valved Stent (AVS) to Correct Severe Tricuspid Regurgitation Patients
NaviGate Cardiac Structures Inc. (“NCSI”) announced today “exceptional results” for implantation of its GATE™ catheter-guided tricuspid atrioventricular valved stent (AVS) at six-week follow-up in two nonagenarian patients presenting with severe tricuspid valve insufficiency.
Genomic Health and Cleveland Diagnostics Announce Strategic Collaboration to Develop and Commercialize New Prostate Cancer Tests
Genomic Health, Inc. (Nasdaq : GHDX ), the world's leading provider of genomic-based diagnostic tests, and Cleveland Diagnostics, Inc., a biotechnology company focused on developing next-generation diagnostics technology for the detection of cancers, today announced an exclusive licensing agreement to develop and commercialize new prostate cancer tests based on Cleveland Diagnostics' IsoPSA™ reagents and technology.
Quest Diagnostics to acquire Cleveland Clinic spinoff Cleveland HeartLab
Quest Diagnostics signed a deal with Cleveland Clinic spinoff Cleveland HeartLab to acquire the company before the end of the year.
ClearFlow, Inc. Announces Positive US Clinical Trial Results
ClearFlow, Inc., a medical device company based in Anaheim, California, announced today that positive clinical trial results were presented at the International Coronary Congress (ICC) 2017 annual meeting on August 18th, 2017 in New York City, NY.
Exclusive: Woman Can Move Again After a Breakthrough Stroke Treatment
The first person to receive deep brain stimulation (DBS) for stroke recovery is performing far better than her doctors anticipated.
ClearFlow, Inc. Receives FDA Clearance for FlowGlide Technology for Cardiac Surgery Patients
ClearFlow, Inc., a medical device company based in Anaheim, California, announced today that the United States Food & Drug Administration (FDA) has granted 510[k] clearance for the company’s proprietary FlowGlide™ Active Clearance Technology® System.
Cleveland Clinic-led Study Finds That New Blood Test is More Accurate in Predicting Overall Risk of Prostate Cancer than Standard Prostate-Specific Antigen (PSA)
A team of researchers from Cleveland Clinic, Louis Stokes Cleveland VA Medical Center, Kaiser Permanente Northwest, and other clinical sites have demonstrated that a new blood test known as IsoPSA detects prostate cancer more precisely than current tests in two crucial measures – distinguishing cancer from benign conditions, and identifying patients with high-risk disease.
ERT Acquires Imaging Solution from Cleveland Clinic
ERT, a global data and technology company that minimizes uncertainty and risk in clinical trials, today announced the acquisition of ImageIQ, originally established as Cleveland Clinic’s Biomedical Imaging and Analysis Center. The acquisition enables ERT to offer advanced, end-to-end clinical trial imaging analysis using best-in-class technology that delivers compliant data for use in clinical development.
Cleveland Clinic spinoff that makes head impact monitoring technology raises $6 million in new financing
Prevent Biometrics, a Cleveland Clinic spinoff based in suburban Minneapolis that makes head impact monitoring technology, announced it has raised $6 million in new financing.
A Cleveland Clinic spinoff is trying to get ahead with a mouth guard that helps detect concussions
A Cleveland Clinic spinoff based in suburban Minneapolis is raising money to continue to develop a head impact-monitoring mouth guard that aims to reduce undetected concussions.